HOME >> BIOLOGY >> NEWS
Phase III clinical program evaluates lubiprostone

BETHESDA, MD May 16, 2005 Takeda Pharmaceuticals North America (TPNA) and Sucampo Pharmaceuticals announced the initiation of a phase III clinical development program for lubiprostone in patients with constipation-predominant irritable bowel syndrome (IBS-C). Enrollment for these trials begins this month. Lubiprostone is an investigational compound currently being evaluated by the FDA for the treatment of chronic idiopathic constipation and associated pain and bloating in adults.

The IBS-C clinical development program will include two phase III trials. Each trial will examine more than 500 patients for 12 weeks to evaluate the safety and efficacy of lubiprostone.

"Irritable bowel syndrome is a condition that can impact a person's quality of life, but is currently addressed by few available therapies," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine, and principal investigator. "Based on results from our phase II study, we believe lubiprostone may have the potential to treat IBS-C, and thus offer a new option for people living with irritable bowel syndrome."

The program includes two double-blind, randomized phase III clinical trials with a treatment period of 12 weeks, taking place at up to 130 sites around the United States. A previous phase II study in IBS-C patients evaluated the effectiveness across a range of doses. Additionally, studies of lubiprostone in chronic constipation have achieved clinical endpoints of relief of constipation and associated pain and bloating and demonstrated tolerability, regardless of gender.

Lubiprostone is a chloride channel activator, a novel compound with a unique mechanism of action. Taken orally, the agent has been shown to work locally and specifically in the GI tract by activating a specific chloride channel (CLC2). Chloride channels are proteins that carry chloride on cells lining the small intestine. When activated, these cells increase in
'"/>


16-May-2005


Page: 1 2

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
3. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
6. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
7. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
8. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
9. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
10. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
11. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase III clinical program evaluates lubiprostone

(Date:8/20/2014)... /CNW/ -  Issue Serious allergic reactions ... life threatening for some children.    What you ... have food allergies and this number may be increasing, especially ... estimated to have food allergies.  The symptoms ... hives to breathing difficulties and loss of consciousness. Symptoms can ...
(Date:8/20/2014)... of the Para and Mato Grosso states of Brazil. ... in order to deforest the land. Deforestation is the ... the land is thereafter converted to a nonforest use. ... ranches, or urban use. The herringbone-patterned tan lines cutting ... the middle of the image are evidence of deforestation ...
(Date:8/20/2014)... Bay Area Lyme Foundation, which aims to make Lyme ... new research published in an upcoming issue of the ... . The findings show that ticks that carry ... year, making the threat of Lyme disease year-round. The ... Public Health (CDPH) Vector-borne Disease Section and University of ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
(Date:8/21/2014)... A Finnish-Swedish research group at the Institute for ... Karolinska institutet, Stockholm, has developed a novel "man ... infection. This innovative diagnostic aid was described in ... August. The method is based on computer vision ... systems combined with visualization of only the diagnostically ...
(Date:8/21/2014)... Aug. 21, 2014 Telomere Biosciences, LLC ... Nutraceutical "TELO-20 for Dogs" with Telomerase Activation ... in the world for dogs. Telomeres are the ... in the body. A wealth of ground-breaking research ... Telomere Science and Aging, including Nobel laureates, has ...
(Date:8/21/2014)... 2014  China Cord Blood Corporation (NYSE: ... release financial results for the first quarter of fiscal ... close in the US.  The Company ... on Friday, August 29, 2014 to discuss its financial ... recent developments, followed by a question and answer session.  ...
(Date:8/21/2014)... SoundConnect , a unified ... one of the nation’s Fastest Growing Private Companies ... 2nd consecutive year. Inc. magazine today ranked SoundConnect ... an exclusive ranking of the nation's fastest-growing private ... at the most important segment of the economy—America’s ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
Cached News: